Curium enhances its position in the French PET market with the completion of the acquisition of Cyclopharma’s French commercial and manufacturing operations

Combined business has a network of 13 PET radiopharmacies across France with a comprehensive coverage of all 140 PET centres in the country and providing life-saving PET diagnostic solutions to more than 320,000 patients annually; The acquisition expands Curium’s PET network in Europe to 25 sites.

Paris, May 02, 2018 (GLOBE NEWSWIRE) -- Curium has successfully completed its previously announced acquisition of the French commercial and manufacturing operations of Cyclopharma, a leading developer and manufacturer of PET diagnostics.

The acquisition brings together two leading players in Radiopharmaceuticals with a combined workforce of 200 personnel with significant expertise and track record in the development, manufacturing and commercialization of diagnostic PET tracers. Cyclopharma’s network of 7 PET radiopharmacies complements the current footprint of Curium’s 6 sites, enabling the combined group to provide a comprehensive coverage of all 140 PET centers across France.

The significantly enhanced capacity would further enable Curium Group to deliver on its commitment for best-in-class reliability to its customers and patients, besides enabling it to meet the growing demand from both existing and soon to be launched PET tracers. Together the expanded group will provide life-saving diagnostic solutions in oncology and neurology to more than 320,000 patients annually across France.

Cyclopharma’s existing R&D and International operations will be carved-out and retained by its current majority shareholder, DENOS Group who intend to focus on the development of innovative tracers.

Commenting on the announcement, Renaud Dehareng, CEO of Curium Group, said: “The acquisition of Cylopharma is transformational to our PET operations in France and expands our PET network across Europe to 25 sites. We intend to leverage this network for making further investments into innovative PET tracers and offer ourselves as a manufacturing and commercialization platform of choice for development stage companies looking for partners”

Benoit Woessmer, Vice President of Curium’s Southern European operations said: “We are excited about the acquisition and the value the combined group can offer to our customers and patients across France. We are pleased to welcome our new colleagues to Curium Group and look forward to working with them in the next leg of our journey”






About Curium

Curium is a world-class nuclear medicine solutions provider with more than a century of industry experience. Formed by the union of IBA Molecular and Mallinckrodt Nuclear Medicine LLC, Curium is the largest vertically integrated radiopharmaceutical product manufacturer in the industry.

With more than 50 manufacturing facilities across Europe and the United States, Curium supports over 14 million patients around the world with SPECT, PET, and therapeutic radiopharmaceuticals to provide potentially life-saving diagnostic solutions. Curium’s products are currently commercialized in more than 60 countries across the globe. 

The Curium brand name is inspired by the work of radiation researchers Marie and Pierre Curie and emphasizes a focus on nuclear medicine.

To learn more, visit



Contact Data